However, the company’s sales inched up 1.15% to RON217 million, from RON214.6 million in the first nine months of 2013, fueled by a 30.2% increase in exports.
Domestic sales were down 6.85% year-on-year, Antibiotice said in its financial report.
Operating profit fell to RON30.84 million in the January-September period, from RON36.03 million in the year-ago months.
For the whole of 2013, Antibiotice estimates a net profit of RON28.6 million, up from RON27.1 million in the previous year.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 10% stake.
Thursday, Antibiotice closed up 0.18% at RON0.561 a share in Bucharest. (EUR1=RON4.4536)